Key result
Baseline serum sFas and sFasL fail to predict CKD progression in children.
Why the study?
Do serum and urinary levels of sFas, sFasL, and sE-selectin predict CKD progression in children?
Cohort (n=173)
Do serum and urinary levels of sFas, sFasL, and sE-selectin predict CKD progression in children?
Answers are grounded in this paper and cite their sources.
Although sFas, sFasL, and sE-selectin levels are elevated in children with CKD, they do not serve as reliable predictors of disease progression.
Background: Chronic kidney disease (CKD) is a rare condition that causes significant health problems in children. Objectives: To evaluate changes in serum and urinary levels of soluble Fas (sFas), soluble Fas Ligand (sFasL), and soluble E-selectin (sE-selectin) over time in children with CKD and determine their potential as biomarkers for CKD progression. Methods: This longitudinal study was conducted as part of the PROGRESS study. A total of 117 patients with CKD and 56 healthy children were included. The CKD cohort underwent a 24-month prospective follow-up. Soluble Fas, sFasL, and sE-selectin levels were measured using the Luminex method at baseline, the 12th month, and the 24th month of the study. Results: At baseline, patients with CKD had significantly higher serum median levels of sFas, sFasL, and sE-selectin compared to the control group (8337 pg/mL vs. 3951 pg/mL, 68 pg/mL vs. 33 pg/mL, and 26460 pg/mL vs. 19801 pg/mL, respectively; P < 0.0001 for all). Additionally, the CKD group showed significantly higher urinary ratios of sFas/Cr, sFasL/Cr, and sE-selectin/Cr compared to the control group (P < 0.0001 for all). In the CKD group, median serum sFasL levels (68 pg/mL vs. 51 pg/mL) and urinary sFasL/Cr ratios (19 pg/mg vs. 14 pg/mg) significantly decreased at the 24th month compared to baseline (P < 0.0001 for both). Similarly, serum sE-selectin median levels and urinary sE-selectin/Cr ratios showed significant decreases over time (P = 0.003 and P < 0.0001, respectively). Baseline urinary sFas/Cr, sFasL/Cr, and sE-selectin/Cr ratios were highest in CKD stages 4 - 5 compared to stages 2, 3a, and 3b (P < 0.0001, P < 0.0001, and P = 0.007, respectively), while no significant differences were observed in baseline serum levels of sFas, sFasL, and sE-selectin across CKD stages (P > 0.05). Baseline serum sFasL median levels were lower (P = 0.038), while baseline serum sFas median levels were higher (P = 0.045) in patients with rapid CKD progression compared to those without rapid progression. Urinary sFas/Cr, sFasL/Cr, and sE-selectin/Cr ratios positively correlated with all urinary HSP/Cr ratios (P < 0.0001 for all). Conclusions: Our study highlights that CKD progression is a complex process involving sFas, sFasL, and sE-selectin; however, these biomarkers do not serve as predictors of CKD progression.
No takes yet. Share an insight, caveat, or question.
Aksu et al. (2024) conducted a cohort in Chronic kidney disease (CKD) (n=173). sFas, sFasL, and sE-selectin levels vs. Healthy children and patients without rapid progression was evaluated on CKD progression. Baseline serum sFas and sFasL levels differed in patients with rapid CKD progression, but these biomarkers did not serve as predictors of CKD progression.
Synapse has enriched 10 related papers. Consider them for comparative context: